175 related articles for article (PubMed ID: 16289813)
1. Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors.
Majerz-Maniecka K; Musiol R; Nitek W; Oleksyn BJ; Mouscadet JF; Le Bret M; Polanski J
Bioorg Med Chem Lett; 2006 Feb; 16(4):1005-9. PubMed ID: 16289813
[TBL] [Abstract][Full Text] [Related]
2. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors.
Majerz-Maniecka K; Musiol R; Skórska-Stania A; Tabak D; Mazur P; Oleksyn BJ; Polanski J
Bioorg Med Chem; 2011 Mar; 19(5):1606-12. PubMed ID: 21316973
[TBL] [Abstract][Full Text] [Related]
3. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors.
Courcot B; Firley D; Fraisse B; Becker P; Gillet JM; Pattison P; Chernyshov D; Sghaier M; Zouhiri F; Desmaële D; d'Angelo J; Bonhomme F; Geiger S; Ghermani NE
J Phys Chem B; 2007 May; 111(21):6042-50. PubMed ID: 17488111
[TBL] [Abstract][Full Text] [Related]
4. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
5. Experimental/theoretical electrostatic properties of a styrylquinoline-type HIV-1 integrase inhibitor and its progenitors.
Firley D; Courcot B; Gillet JM; Fraisse B; Zouhiri F; Desmaële D; d'Angelo J; Ghermani NE
J Phys Chem B; 2006 Jan; 110(1):537-47. PubMed ID: 16471566
[TBL] [Abstract][Full Text] [Related]
6. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
Garofalo A; Grande F; Brizzi A; Aiello F; Dayam R; Neamati N
ChemMedChem; 2008 Jun; 3(6):986-90. PubMed ID: 18383063
[TBL] [Abstract][Full Text] [Related]
7. Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor.
Vandurm P; Cauvin C; Guiguen A; Georges B; Le Van K; Martinelli V; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4806-9. PubMed ID: 19556126
[TBL] [Abstract][Full Text] [Related]
8. Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.
Serafin K; Mazur P; Bak A; Laine E; Tchertanov L; Mouscadet JF; Polanski J
Bioorg Med Chem; 2011 Aug; 19(16):5000-5. PubMed ID: 21767953
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
[TBL] [Abstract][Full Text] [Related]
10. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.
Sun XH; Guan JQ; Tan JJ; Liu C; Wang CX
SAR QSAR Environ Res; 2012 Oct; 23(7-8):683-703. PubMed ID: 22991976
[TBL] [Abstract][Full Text] [Related]
12. Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity.
Bénard C; Zouhiri F; Normand-Bayle M; Danet M; Desmaële D; Leh H; Mouscadet JF; Mbemba G; Thomas CM; Bonnenfant S; Le Bret M; d'Angelo J
Bioorg Med Chem Lett; 2004 May; 14(10):2473-6. PubMed ID: 15109635
[TBL] [Abstract][Full Text] [Related]
13. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
14. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Neamati N
ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring.
Metobo SE; Jin H; Tsiang M; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):3985-8. PubMed ID: 16723226
[TBL] [Abstract][Full Text] [Related]
17. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors.
Fardis M; Jin H; Jabri S; Cai RZ; Mish M; Tsiang M; Kim CU
Bioorg Med Chem Lett; 2006 Aug; 16(15):4031-5. PubMed ID: 16716589
[TBL] [Abstract][Full Text] [Related]
18. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
19. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
20. Rational design of novel diketoacid-containing ferrocene inhibitors of HIV-1 integrase.
da Silva CH; Del Ponte G; Neto AF; Taft CA
Bioorg Chem; 2005 Aug; 33(4):274-84. PubMed ID: 16023487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
